Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

09 August 2025 : Review article

Andrzej Silczuk

^{ADEF 1}, Robert J. Madejek

^{BCDF 1*}, Tytus Koweszko

^{BCDEF 1}, Paulina Mularczyk-Tomczewska

^{BF 2}, Ewelina Adamska^{BEF 1}, Mariusz Gujski

^{BF 2}, Agata Szulc

^{BF 3}

DOI: 10.12659/MSM.948302

Med Sci Monit 2025; 31:e948302

Authors information Article notes Copyright and License information

Introduction Methodology Clinical Applications Conditions for Conducting the Session Summary of Current Knowledge on the Course of Psychedelic Psychotherapy Safety and Ethical Considerations Key Conclusions on Psychedelic-Assisted Psychotherapy and Navigating the Future of Psychedelic-Assisted Therapy: Research, Ethics, and Clinical Practice References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Receptor mechanisms of selected psychedelics.

	5-HT1A agonist	5-HT2A agonist	5-HT2C agonist	NMDA antagonist	SNDRA
LSD		+	+
Psylocybin	+	+
MDMA		+			+
Ketamine				+
Ayahuasca		+
DMT	+	+	+
DMT – N,N-dimethyltryptamine; 5-HT – 5-hydroxytryptamine; LSD – d-lysergic acid diethylamide; MDMA – 3,4-methylenedioxymethamphetamine; NMDA – N-methyl-D-aspartate; SNDRA – serotonin-norepinephrine-dopamine realizing agent.

Back to the Article